Key facts
- Cordio’s last known valuation is $38.3M (Jun 2022).
- It has raised $30.3M; the latest was Later Stage VC ($1.3M) in Oct 2025.
- Notable investors include OurCrowd, Peregrine Ventures, Ceros., AxessVentures, BeyondBio (Isarel) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cordio
- ·The full record, as it builds
Funding rounds
No funding rounds for Cordio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cordio
Developer of a speech processing platform designed for monitoring health conditions through the voice of patients. The company's platform permits near real-time monitoring and early detection of condition deterioration, which is based on true speech signal processing technology, specific to each patient and augmented with machine learning capabilities, enabling physicians and patients to identify and mitigate condition worsening by helping physicians to prevent patient deterioration and hospitalization while keeping the patient's well-being at the core.
- Sector
- Healthcare
- HQ
- Or-Yehuda, Israel
- Founded
- 2013
- Employees
- 31
- Website
- cordio-med.com/
- Ownership
- Privately Held (backing)
Cordio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cordio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cordio in its N-PORT filings yet. We sweep new filings monthly.